For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine ...

Patients with rheumatoid arthritis are at an increased risk for venous thromboembolism, regardless of age, sex, BMI, and ...

One of the highest yields you can get right now is from Pfizer (NYSE: PFE). The healthcare giant offers a yield of 6.8%, ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Pfizer is advancing research and building a comprehensive "toolbox" for Vietnamese patients, combining innovative vaccines, ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

New research on eltrombopag plus immunosuppressive therapy for severe aplastic anemia in young patients challenges the ...

Pfizer Canada ULC and BioNTech SE (Nasdaq: BNTX) “BioNTech” announced today that Health Canada has authorized the LP.8.1 ...

Pfizer's Canadian unit and BioNTech said they have received approval in Canada for their updated Comirnaty Covid-19 vaccine. The companies said Monday the updated vaccine targets the Omicron LP.8.1 ...

President Trump wrote to major drug companies, informing them that they had to comply with his “Most Favored Nation” order.

With Trump's backing, the pharma industry is leaning into the idea of more "direct-to-consumer" sales. But experts say the ...